Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-masked, Active-controlled, Multi-center Phase 2 Clinical Study Evaluating the Efficacy and Safety of 0.5% and 1.0% VVN461 Ophthalmic Solution in Patients with Noninfectious Anterior Uveitis

Next Previous
Trial Profile

A Randomized, Double-masked, Active-controlled, Multi-center Phase 2 Clinical Study Evaluating the Efficacy and Safety of 0.5% and 1.0% VVN461 Ophthalmic Solution in Patients with Noninfectious Anterior Uveitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VVN 461 (Primary) ; Prednisolone acetate
  • Indications Uveitis
  • Focus Therapeutic Use
  • Sponsors VivaVision Biotech

Most Recent Events

  • 24 Apr 2025 According to a the VivaVision Biotech Media Release, full data will be reported in future publications in conferences and journals.
  • 24 Apr 2025 Results presented in the VivaVision Biotech Media Release.
  • 27 Jan 2025 Status changed from discontinued to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top